How biotechs can recover VAT on EU-based clinical trials
At a time when companies are managing more expensive clinical trials with less funding, any opportunity to reduce trial costs…
At a time when companies are managing more expensive clinical trials with less funding, any opportunity to reduce trial costs…
The US Food and Drug Administration (FDA) has lifted a clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114…
President Donald Trump has signed an executive order for the US to leave the World Health Organization (WHO). As one…
It has been a turbulent time for the pharmaceutical industry – especially in regard to the clinical trial sector. From…
AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD)…
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting…
Cancer immunotherapy biotech I-Mab, has paused the development of uliledlimab in favour of its now lead candidate givastomig. The Maryland,…
From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure prophylaxis (PrEP) drugs, 2024 has been a busy year…
Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a Phase II trial in patients with painful lumbosacral radiculopathy (LSR)…
Diversity has been a huge buzzword in the clinical trial space in the past few years. There has been a…